

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
01 February 2024 (01.02.2024)



(10) International Publication Number
WO 2024/023771 A1

(51) International Patent Classification:

C07K 16/28 (2006.01) A61K 39/395 (2006.01)
A61K 31/436 (2006.01) A61K 47/68 (2017.01)
A61K 31/437 (2006.01) C07K 16/30 (2006.01)
A61K 38/17 (2006.01) A61P 35/00 (2006.01)

(21) International Application Number:

PCT/IB2023/057657

(22) International Filing Date:

27 July 2023 (27.07.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/369,718 28 July 2022 (28.07.2022) US

(71) Applicant: **MEDIMMUNE, LLC** [US/US]; One MedImmune Way, Gaithersburg, Maryland 20878 (US).

(72) Inventors: **OMAR, Bilal**; c/o AstraZeneca Pharmaceuticals LP, 1800 Concord Pike, P.O. Box 15437, Wilmington, Delaware 19850-5437 (US). **HAMMOND, Scott A.**; c/o MedImmune, LLC, One MedImmune Way, Gaithersburg, Maryland 20878 (US). **KINNEER, Krista**; c/o MEDIMMUNE, LLC, One MedImmune Way, Gaithersburg, Maryland 20878 (US). **FREEMAN, Daniel J.**; c/

o AstraZeneca Pharmaceuticals LP, 1800 Concord Pike, P.O. Box 15437, Wilmington, Delaware 19850-5437 (US). **ZERON-MEDINA CUAIRAN, Jorge**; c/o AstraZeneca Pharmaceuticals LP, 1800 Concord Pike, P.O. Box 15437, Wilmington, Delaware 19850-5437 (US). **ACHOUR, Ilkel**; c/o AstraZeneca Pharmaceuticals LP, 1800 Concord Pike, P.O. Box 15437, Wilmington, Delaware 19850-5437 (US). **PALMER, Doug**; c/o AstraZeneca Pharmaceuticals LP, 1800 Concord Pike, P.O. Box 15437, Wilmington, Delaware 19850-5437 (US). **ANDERTON, Judith**; c/o AstraZeneca UK Limited, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge Cambridgeshire CB2 0AA (GB). **LUHESHI, Nadia**; c/o AstraZeneca UK Limited, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge Cambridgeshire CB2 0AA (GB).


(74) Agent: **REHFUSS, Patrick**; AstraZeneca Pharmaceuticals, Legal, IP, One MedImmune Way, Gaithersburg, Maryland 20878 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,

(54) Title: COMBINATION THERAPIES FOR TREATMENT OF CANCER

FIG. 8D

CT26 Survival Efficacy of Two Doses ADC with PDL1



(57) Abstract: Provided herein are methods of treating cancer in a human subject, comprising administering to the subject: i) an antibody-drug conjugate (ADC) comprising an antibody, a cleavable linker and a cytotoxic agent, and ii) a bispecific checkpoint inhibitor. Further provided herein are kits comprising i) an antibody-drug conjugate (ADC) comprising an antibody, a cleavable linker and a cytotoxic agent, and ii) a bispecific checkpoint inhibitor.

[Continued on next page]

KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

- (84) Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*